People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.